PureTech Health (PRTC) Share Price, News & Analysis

Company Overview

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: 126.20 to 128
• 50-Day Range: 103 to 147.20
• 52-Week Range: 100.40 to 238.50
• Volume: 245,507 shs
• Average Volume: 913,893 shs
• Market Capitalization: £380.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 455
• Consensus Rating: Buy

PRTC Stock Analysis - Frequently Asked Questions

How have PRTC shares performed this year?

PureTech Health's stock was trading at GBX 150.20 at the beginning of the year. Since then, PRTC shares have decreased by 14.8% and is now trading at GBX 128.
View the best growth stocks for 2025 here.

How do I buy shares of PureTech Health?

Shares of PRTC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of PureTech Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PureTech Health investors own include IQE (IQE), Royal Dutch Shell (RDSB), BP (BP), GSK (GSK), Hummingbird Resources (HUM), Plug Power (PLUG) and AstraZeneca (AZN).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:PRTC
• CIK: N/A
• Web: puretechhealth.com
• Phone: +1-617-4822333
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 455
• High Stock Price Target: GBX 455
• Low Stock Price Target: GBX 455
• Potential Upside/Downside: +255.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (24.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-91,861,623.85
• Net Margins: -17,620.94%
• Pretax Margin: N/A
• Return on Equity: -21.15%
• Return on Assets: -13.39%

Debt

• Debt-to-Equity Ratio: 45.82
• Current Ratio: 3.68
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: £521,320.79
• Price / Sales: 737.53
• Cash Flow: GBX 59.77 per share
• Price / Cash Flow: 2.14
• Book Value: GBX 113.55 per share
• Price / Book: 1.13

Miscellaneous

• Outstanding Shares: 300,381,095
• Free Float: N/A
• Market Cap: £384.49 million
• Optionable: Not Optionable
• Beta: 1.02